Effect of an Oral Acerola Juice Powder on Skin Beauty Parameters in Women Exposed to Environmental Stresses

NCT07229131 | Completed

• 1 other identifier: GZ25205020P
• Study Type: interventional
• Target: 108
• Locations: 1 country
• Sites: 1

Brief Summary

The study is being conducted to evaluate the efficacy and the safety of an oral acerola-based product on skin ageing parameters.

Conditions

Pollution; Exposure

Keywords

Skin; Beauty; Environmental stress; Acerola; Vitamin C; Polyphenols

Outcome Measures

Primary Outcomes (1)

• Change from baseline on skin translucency parameter Alpha at 84 days

  The skin translucency parameter Alpha is measured with translucency meter

  From enrollment to 84 days of supplementation

Secondary Outcomes (6)

• Change from baseline on skin translucency parameters Alpha, Area and K at 28 days and 84 days

  From enrollment to 28 days of supplementation

• Change from baseline on skin complexion radiance at 14, 28, 56 and 84 days

  From enrollment to 14, 28, 56 and 84 days of supplementation

• Change from baseline on pigment spot at 14, 28, 56 and 84 days

  From enrollment to 14, 28, 56 and 84 days of supplementation

• Change from baseline on skin firmness, elasticity and fatigability at 28 and 84 days

  From enrollment to 28 and 84 days of supplementation

• Change from baseline on Trans Epidermal Water Loss at 28 and 84 days

  From enrollment to 28 and 84 days of supplementation

Other Outcomes (4)

• Change from baseline on skin pH at 28 and 84 days

  From enrollment to 28 and 84 days of supplementation

• Change from baseline on blood flow at 28 and 84 days

  From enrollment to 28 and 84 days of supplementation

• Change from baseline on subject quality of life at 28 and 84 days

  From enrollment to 28 and 84 days of supplementation

Study Arms (3)

Acerola Juice Powder 1200 mg/day

EXPERIMENTAL

Higher dose

Dietary Supplement: Acerola Juice Powder 1200 mg/day

Acerola Juice Powder 600 mg/day

EXPERIMENTAL

Lower dose

Dietary Supplement: Acerola Juice Powder 600 mg/day

Placebo

PLACEBO COMPARATOR

Placebo

Other: Placebo

Interventions

Acerola Juice Powder 1200 mg/day DIETARY_SUPPLEMENT

4 capsules per day, each capsule containing 300mg of Acerola and 100 mg of maltodextrin

Acerola Juice Powder 1200 mg/day

Acerola Juice Powder 600 mg/day DIETARY_SUPPLEMENT

4 capsules/day, each capsule containing 150 mg of Acerola and 250 mg of Maltodextrin

Acerola Juice Powder 600 mg/day

Placebo OTHER

4 capsules per day, each capsule containing 400 mg of maltodextrin

Placebo

Eligibility Criteria

• Age: 30 Years - 60 Years
• Gender Eligibility Details: Female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy women.
• Chinese.
• Age: in each group of products
• % of subject having 30 to 45 years old
• % of subject having 46 to 60 years old
• Phototype: II to IV.
• Subject with dull skin from grade 3 to 7 on skin dullness 9 points scale.
• Subject exposed to high air pollution up to 2 to 3 hours per day (traffic roads, cigarette smoke, dusts or small particles).
• Subject who accepts daily exposition to blue light (mobile phone, Ipad, laptop or get exposure to LED light) at home (at least 2h).
• Subject with at least 1 spot on the face.
• Subject with BMI ≤ 30
• Subject, psychologically able to understand the study related information and to give a written informed consent.
• Subject having given freely and expressly her informed consent.
• Subject agreeing to not change her alimentary and cosmetic habits on the studied area during the study.

You may not qualify if:

• In term of population :
• Pregnant or nursing woman or planning a pregnancy during the study.
• Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.
• Minor subject.
• Major subject who is under guardianship or who is not able to express her consent.
• Subject in a social or sanitary establishment.
• Subject suspected to be non-compliant according to the investigator's judgment.
• In term of associated pathology :
• Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk.
• Subject suffering from a severe or progressive disease.
• Subject with known history of or suffering from skin disease that may interfere with evaluation of the study results and/or subject safety.
• Subject having history of severe allergy or anaphylactic shock including known risk of hypersensitivity to one of the components of the composition of the product
• Related to previous or ongoing treatment :
• Subject undergoing a topical treatment on the test area or a systemic treatment:
• anti-inflammatory medication and/or anti-histamines during the previous 2 weeks and during the study;

Sponsors & Collaborators

• Diana SAS: lead
• Eurofins Dermscan Pharmascan: collaborator

Study Sites (1)

EUROFINS CONSUMER PRODUCT TESTING (Guangzhou)Co.,Ltd.

Guangzhou, China

Location

Study Officials

• Sarah ZENG

  EUROFINS CONSUMER PRODUCT TESTING (Guangzhou)Co.,Ltd.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Double-blind, randomised, placebo-controlled study

Study Record Dates

• First Submitted: November 13, 2025
• First Posted: November 14, 2025
• Study Start: November 3, 2025
• Primary Completion: February 13, 2026
• Study Completion: February 13, 2026
• Last Updated: February 18, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)